$PTPI
Petros Pharmaceuticals, Inc.

2024 Q3 Form 10-Q Financial Statement

#000141057824001437 Filed on August 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2023 Q2
Revenue $1.576M $1.421M $1.994M
YoY Change -5.87% -28.71% -52.37%
Cost Of Revenue $287.0K $329.1K $513.9K
YoY Change -29.74% -35.95% -20.85%
Gross Profit $1.289M $1.092M $1.480M
YoY Change 1.83% -26.2% -58.16%
Gross Profit Margin 81.79% 76.85% 74.23%
Selling, General & Admin $2.301M $2.287M $2.250M
YoY Change 14.95% 1.65% -30.06%
% of Gross Profit 178.48% 209.33% 151.98%
Research & Development $588.4K $368.8K $866.6K
YoY Change 51.21% -57.44% 105.72%
% of Gross Profit 45.63% 33.76% 58.55%
Depreciation & Amortization $739.4K $717.8K $826.8K
YoY Change -10.56% -13.18% -47.03%
% of Gross Profit 57.35% 65.71% 55.86%
Operating Expenses $3.629M $3.373M $3.943M
YoY Change -40.24% -14.45% -24.16%
Operating Profit -$2.340M -$2.281M -$2.463M
YoY Change -51.32% -7.39% 48.24%
Interest Expense $119.1K $1.619M -$80.00K
YoY Change -130.31% -2123.6% -46.8%
% of Operating Profit
Other Income/Expense, Net $119.1K $1.619M -$83.88K
YoY Change -81.68% -2030.11%
Pretax Income -$2.221M -$662.0K -$2.550M
YoY Change -51.19% -74.04% 40.74%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$2.221M -$662.0K -$2.547M
YoY Change -51.19% -74.0% 40.56%
Net Earnings / Revenue -140.87% -46.57% -127.72%
Basic Earnings Per Share -$0.53 -$0.37 -$1.20
Diluted Earnings Per Share -$0.53 -$0.37 -$1.20
COMMON SHARES
Basic Shares Outstanding 9.607M 7.000M 2.114M
Diluted Shares Outstanding 9.830M 7.388M 2.118M

Balance Sheet

Concept 2024 Q3 2024 Q2 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.895M $7.460M $7.380M
YoY Change -78.33% 1.08% -44.49%
Cash & Equivalents $3.900M $7.500M $7.400M
Short-Term Investments
Other Short-Term Assets $4.760K $86.55K $31.74K
YoY Change -91.73% 172.65% -75.53%
Inventory $1.406M $1.433M $2.180M
Prepaid Expenses
Receivables $1.949M $1.777M $2.577M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $10.72M $13.98M $13.15M
YoY Change -56.11% 6.3% -42.46%
LONG-TERM ASSETS
Property, Plant & Equipment $18.82K $23.85K $34.07K
YoY Change -40.28% -30.0% -23.08%
Goodwill
YoY Change
Intangibles $6.826M $7.541M $10.60M
YoY Change -30.15% -28.83% -52.22%
Long-Term Investments
YoY Change
Other Assets $3.124M $3.625M $294.4K
YoY Change -29.26% 1131.43% -94.7%
Total Long-Term Assets $9.969M $11.19M $15.58M
YoY Change -31.16% -28.16% -44.76%
TOTAL ASSETS
Total Short-Term Assets $10.72M $13.98M $13.15M
Total Long-Term Assets $9.969M $11.19M $15.58M
Total Assets $20.69M $25.17M $28.73M
YoY Change -46.82% -12.38% -43.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.601M $791.1K $1.784M
YoY Change 18.15% -55.65% -6.34%
Accrued Expenses $6.539M $6.674M $4.779M
YoY Change 69.02% 39.66% 19.23%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.326M $1.937M $1.120M
YoY Change 104.14% 72.95% 23.78%
Total Short-Term Liabilities $12.56M $9.976M $7.965M
YoY Change 55.43% 25.25% 7.98%
LONG-TERM LIABILITIES
Long-Term Debt $4.923M $5.697M $7.630M
YoY Change -32.09% -25.33% -16.34%
Other Long-Term Liabilities $91.83K $107.8K $183.3K
YoY Change -39.34% -41.22% -45.46%
Total Long-Term Liabilities $91.83K $107.8K $183.3K
YoY Change -39.34% -41.22% -45.46%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.56M $9.976M $7.965M
Total Long-Term Liabilities $91.83K $107.8K $183.3K
Total Liabilities $17.58M $15.98M $15.78M
YoY Change -44.83% 1.27% -6.24%
SHAREHOLDERS EQUITY
Retained Earnings -$103.9M -$101.7M -$94.70M
YoY Change 4.74% 7.39% 29.73%
Common Stock $1.002K $930.00 $211.00
YoY Change 374.88% 340.76% -89.8%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.116M $8.070M $12.94M
YoY Change
Total Liabilities & Shareholders Equity $20.69M $25.17M $28.73M
YoY Change -46.82% -12.38% -43.73%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2023 Q2
OPERATING ACTIVITIES
Net Income -$2.221M -$662.0K -$2.547M
YoY Change -51.19% -74.0% 40.56%
Depreciation, Depletion And Amortization $739.4K $717.8K $826.8K
YoY Change -10.56% -13.18% -47.03%
Cash From Operating Activities -$771.2K -$1.662M -$570.0K
YoY Change -80.94% 191.64% -86.43%
INVESTING ACTIVITIES
Capital Expenditures $19.14K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$19.14K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.775M -1.958M -360.0K
YoY Change -118.97% 443.98% 103.42%
NET CHANGE
Cash From Operating Activities -771.2K -1.662M -570.0K
Cash From Investing Activities -19.14K
Cash From Financing Activities -2.775M -1.958M -360.0K
Net Change In Cash -3.565M -3.621M -930.0K
YoY Change -133.69% 289.32% -78.75%
FREE CASH FLOW
Cash From Operating Activities -$771.2K -$1.662M -$570.0K
Capital Expenditures $19.14K
Free Cash Flow -$790.4K
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
196760
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6673591
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5360077
CY2024Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
10201758
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001815903
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2024Q2 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
4039
CY2023Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
10022
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9297538
us-gaap Revenue Practical Expedient Financing Component
RevenuePracticalExpedientFinancingComponent
true
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39752
dei Entity Registrant Name
EntityRegistrantName
Petros Pharmaceuticals, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1410058
dei Entity Address Address Line1
EntityAddressAddressLine1
1185 Avenue of the Americas
dei Entity Address Address Line2
EntityAddressAddressLine2
3rd Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10036
dei City Area Code
CityAreaCode
973
dei Local Phone Number
LocalPhoneNumber
242-0005
dei Security12b Title
Security12bTitle
Common stock
dei Trading Symbol
TradingSymbol
PTPI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
9606678
CY2024Q2 us-gaap Cash
Cash
7460014
CY2023Q4 us-gaap Cash
Cash
13336975
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1776531
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2226151
CY2024Q2 us-gaap Inventory Net
InventoryNet
1433217
CY2023Q4 us-gaap Inventory Net
InventoryNet
1610391
CY2024Q2 us-gaap Advances On Inventory Purchases
AdvancesOnInventoryPurchases
1414320
CY2023Q4 us-gaap Advances On Inventory Purchases
AdvancesOnInventoryPurchases
1182899
CY2024Q2 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
1894963
CY2023Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
2033980
CY2024Q2 us-gaap Assets Current
AssetsCurrent
13979045
CY2023Q4 us-gaap Assets Current
AssetsCurrent
20390396
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23846
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
28957
CY2024Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
7541171
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
8971737
CY2024Q2 us-gaap Inventory Noncurrent
InventoryNoncurrent
3471471
CY2023Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
4178446
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
153741
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
226259
CY2024Q2 us-gaap Assets
Assets
25169274
CY2023Q4 us-gaap Assets
Assets
33795795
CY2024Q2 us-gaap Notes Payable Current
NotesPayableCurrent
1936995
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
1156550
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
791091
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1713253
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6673591
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5360077
CY2024Q2 us-gaap Payable Preferred Stock Redeemed
PayablePreferredStockRedeemed
224124
CY2023Q4 us-gaap Payable Preferred Stock Redeemed
PayablePreferredStockRedeemed
2047583
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
350544
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
493288
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
9976345
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10770751
CY2024Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
5697128
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
6857364
CY2024Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
202000
CY2023Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
3550000
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
107756
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
137657
CY2024Q2 us-gaap Liabilities
Liabilities
15983229
CY2023Q4 us-gaap Liabilities
Liabilities
21315772
CY2024Q2 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Temporary Equity Value Excluding Additional Paid In Capital
TemporaryEquityValueExcludingAdditionalPaidInCapital
1000
CY2023Q4 us-gaap Temporary Equity Value Excluding Additional Paid In Capital
TemporaryEquityValueExcludingAdditionalPaidInCapital
1000
CY2024Q2 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
15000
CY2023Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
15000
CY2024Q2 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
4039
CY2024Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
4039
CY2023Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
10022
CY2023Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
10022
CY2024Q2 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
4585929
CY2023Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
11271365
CY2024Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
1115762
CY2023Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
408982
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9297538
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9297538
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2991377
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2991377
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
930
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
298
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
109783623
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
110960324
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-101714270
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-98889581
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
8070283
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
12071041
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25169274
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
33795795
ptpi Revenue From Contract With Customers Excluding Assessed Taxes
RevenueFromContractWithCustomersExcludingAssessedTaxes
2810276
ptpi Revenue From Contract With Customers Excluding Assessed Taxes
RevenueFromContractWithCustomersExcludingAssessedTaxes
4511983
CY2024Q2 ptpi Revenue From Contract With Customers Excluding Assessed Taxes
RevenueFromContractWithCustomersExcludingAssessedTaxes
1421471
CY2023Q2 ptpi Revenue From Contract With Customers Excluding Assessed Taxes
RevenueFromContractWithCustomersExcludingAssessedTaxes
1994011
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
660939
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1064599
CY2024Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
329110
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
513857
us-gaap Gross Profit
GrossProfit
2149337
us-gaap Gross Profit
GrossProfit
3447384
CY2024Q2 us-gaap Gross Profit
GrossProfit
1092361
CY2023Q2 us-gaap Gross Profit
GrossProfit
1480154
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4998088
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4380231
CY2024Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2286630
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2249592
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1924750
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1185668
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
368798
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
866575
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1435677
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1653590
CY2024Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
717838
CY2023Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
826795
us-gaap Operating Expenses
OperatingExpenses
8358515
us-gaap Operating Expenses
OperatingExpenses
7219489
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
3373266
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
3942962
us-gaap Operating Income Loss
OperatingIncomeLoss
-6209178
us-gaap Operating Income Loss
OperatingIncomeLoss
-3772105
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2280905
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2462808
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
3348000
CY2024Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1614000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
271210
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
119241
CY2024Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
119391
CY2023Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
52924
ptpi Interest Expense On Promissory Notes
InterestExpenseOnPromissoryNotes
234721
ptpi Interest Expense On Promissory Notes
InterestExpenseOnPromissoryNotes
278966
CY2024Q2 ptpi Interest Expense On Promissory Notes
InterestExpenseOnPromissoryNotes
114512
CY2023Q2 ptpi Interest Expense On Promissory Notes
InterestExpenseOnPromissoryNotes
136799
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3384489
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-159725
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1618879
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-83875
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2824689
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3931830
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-662026
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2546683
us-gaap Net Income Loss
NetIncomeLoss
-2824689
us-gaap Net Income Loss
NetIncomeLoss
-3931830
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-662026
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2546683
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
812303
CY2024Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
216798
us-gaap Preferred Stock Accretion Of Redemption Discount
PreferredStockAccretionOfRedemptionDiscount
7124871
CY2024Q2 us-gaap Preferred Stock Accretion Of Redemption Discount
PreferredStockAccretionOfRedemptionDiscount
1856095
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10761863
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2734919
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.77
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.77
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.87
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.87
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.20
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.20
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6072349
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6072349
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2103220
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2103220
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7388107
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7388107
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2117581
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2117581
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
9786579
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16834
CY2024Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
100000
CY2024Q2 us-gaap Preferred Stock Accretion Of Redemption Discount
PreferredStockAccretionOfRedemptionDiscount
1856095
CY2024Q2 us-gaap Preferred Stock Redemption Discount
PreferredStockRedemptionDiscount
153842
CY2024Q2 ptpi Preferred Stock Redemption Including Cash Premium
PreferredStockRedemptionIncludingCashPremium
901789
CY2024Q2 ptpi Temporary Equity Redemption Premium
TemporaryEquityRedemptionPremium
62956
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-662026
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
8070283
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
12071041
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
197215
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
210000
us-gaap Preferred Stock Accretion Of Redemption Discount
PreferredStockAccretionOfRedemptionDiscount
7124871
us-gaap Preferred Stock Redemption Discount
PreferredStockRedemptionDiscount
754962
ptpi Preferred Stock Redemption Including Cash Premium
PreferredStockRedemptionIncludingCashPremium
6353890
ptpi Temporary Equity Redemption Premium
TemporaryEquityRedemptionPremium
57341
us-gaap Net Income Loss
NetIncomeLoss
-2824689
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
8070283
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
15447656
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
43316
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2546683
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
12944289
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
16702467
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
173652
us-gaap Net Income Loss
NetIncomeLoss
-3931830
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
12944289
us-gaap Profit Loss
ProfitLoss
-2824689
us-gaap Profit Loss
ProfitLoss
-3931830
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1435677
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1653590
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-25352
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
4499
ptpi Inventory And Sample Inventory Reserve
InventoryAndSampleInventoryReserve
7999
ptpi Inventory And Sample Inventory Reserve
InventoryAndSampleInventoryReserve
41195
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
72517
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
64081
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
3348000
us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
197215
us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
173652
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
210000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-474972
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
470984
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-169175
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-33266
ptpi Increase Decrease In Prepaid Inventories
IncreaseDecreaseInPrepaidInventories
231421
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-845992
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-326992
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-922164
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-22668
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1313514
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1143909
ptpi Increase Decrease Of Deferred Revenue
IncreaseDecreaseOfDeferredRevenue
-117238
ptpi Increase Decrease Of Deferred Revenue
IncreaseDecreaseOfDeferredRevenue
-281372
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-25506
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
24586
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-29901
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-79349
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2797210
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1320433
us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-379791
us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-721034
us-gaap Payments For Repurchase Of Preferred Stock And Preference Stock
PaymentsForRepurchaseOfPreferredStockAndPreferenceStock
2699960
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3079751
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-721034
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5876961
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2041467
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13336975
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9426264
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7460014
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7384797
us-gaap Interest Paid Net
InterestPaidNet
120209
us-gaap Interest Paid Net
InterestPaidNet
278966
ptpi Non Cash Acquisition Active Pharmaceutical Ingredient Of Purchase Agreement
NonCashAcquisitionActivePharmaceuticalIngredientOfPurchaseAgreement
439353
ptpi Noncash Decrease In Api Purchase Commitment Related To Vivus Settlement
NoncashDecreaseInApiPurchaseCommitmentRelatedToVivusSettlement
459422
ptpi Noncash Decrease In Other Current Assets Api Purchase Commitment
NoncashDecreaseInOtherCurrentAssetsApiPurchaseCommitment
20069
ptpi Noncash Issuance Of Common Stock To Non Employee
NoncashIssuanceOfCommonStockToNonEmployee
3
ptpi Noncash Redemption Of Series Convertible Preferred Stock
NoncashRedemptionOfSeriesConvertiblePreferredStock
6353890
ptpi Accrued Series Convertible Preferred Payments Payable
AccruedSeriesConvertiblePreferredPaymentsPayable
224124
ptpi Accretion Of Series Convertible Preferred Stock To Redemption Value
AccretionOfSeriesConvertiblePreferredStockToRedemptionValue
7124871
ptpi Accrual Of Series Convertible Preferred Stock Dividends
AccrualOfSeriesConvertiblePreferredStockDividends
754962
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7500000
CY2024Q2 ptpi Working Capital
WorkingCapital
4000000.0
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-101700000
us-gaap Debt Instrument Periodic Payment Interest
DebtInstrumentPeriodicPaymentInterest
7600000
CY2023Q3 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
15000000
CY2024Q2 ptpi Consecutive Business Days For Maintaining Bid Price Requirement
ConsecutiveBusinessDaysForMaintainingBidPriceRequirement
30
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of revenue and expenses during the reporting periods. Such estimates include the adequacy of accounts receivable reserves, return reserves, inventory reserves, assessment of long-lived assets, including intangible asset impairment, and the valuation of the derivative liability, among others. Actual results could differ from these estimates and changes in these estimates are recorded when known.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Concentration of Credit Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financial instruments that subject the Company to concentrations of credit risk includes cash. The Company maintains cash on deposit at U.S.-based banks in amounts which, at times, may be in excess of insured limits of $250,000.</p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2024Q2 us-gaap Contract With Customer Refund Liability Current
ContractWithCustomerRefundLiabilityCurrent
4900000
CY2023Q4 us-gaap Contract With Customer Refund Liability Current
ContractWithCustomerRefundLiabilityCurrent
4200000
ptpi Amount Of Returns As Reduction Of Gross Revenue
AmountOfReturnsAsReductionOfGrossRevenue
800000
ptpi Amount Of Returns As Reduction Of Gross Revenue
AmountOfReturnsAsReductionOfGrossRevenue
800000
CY2024Q2 ptpi Amount Of Returns As Reduction Of Gross Revenue
AmountOfReturnsAsReductionOfGrossRevenue
300000
CY2023Q2 ptpi Amount Of Returns As Reduction Of Gross Revenue
AmountOfReturnsAsReductionOfGrossRevenue
400000
CY2024Q2 us-gaap Deferred Revenue
DeferredRevenue
0
CY2023Q4 us-gaap Deferred Revenue
DeferredRevenue
100000
CY2024Q2 us-gaap Accounts Receivable Gross
AccountsReceivableGross
2099868
CY2023Q4 us-gaap Accounts Receivable Gross
AccountsReceivableGross
2887317
CY2024Q2 ptpi Accounts Receivable Distribution Service Fees
AccountsReceivableDistributionServiceFees
117049
CY2023Q4 ptpi Accounts Receivable Distribution Service Fees
AccountsReceivableDistributionServiceFees
398968
CY2024Q2 ptpi Accounts Receivable Chargebacks Accruals
AccountsReceivableChargebacksAccruals
5983
CY2023Q4 ptpi Accounts Receivable Chargebacks Accruals
AccountsReceivableChargebacksAccruals
2462
CY2024Q2 ptpi Accounts Receivable Cash Discount Allowances
AccountsReceivableCashDiscountAllowances
22979
CY2023Q4 ptpi Accounts Receivable Cash Discount Allowances
AccountsReceivableCashDiscountAllowances
24639
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
177326
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
235097
CY2024Q2 us-gaap Accounts Receivable Net
AccountsReceivableNet
1776531
CY2023Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
2226151
CY2024Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1321107
CY2023Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1430139
CY2024Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
112110
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
180252
CY2024Q2 us-gaap Inventory Net
InventoryNet
1433217
CY2023Q4 us-gaap Inventory Net
InventoryNet
1610391
CY2024Q2 ptpi Inventory Finished Goods Valuation Reserves
InventoryFinishedGoodsValuationReserves
303410
CY2023Q4 ptpi Inventory Finished Goods Valuation Reserves
InventoryFinishedGoodsValuationReserves
295411
CY2024Q2 us-gaap Prepaid Insurance
PrepaidInsurance
128319
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
45664
CY2024Q2 ptpi Prepaid Food And Drug Administration Fee Current
PrepaidFoodAndDrugAdministrationFeeCurrent
312551
CY2023Q4 ptpi Prepaid Food And Drug Administration Fee Current
PrepaidFoodAndDrugAdministrationFeeCurrent
937652
CY2024Q2 ptpi Prepaid Purchase Commitment Asset Current
PrepaidPurchaseCommitmentAssetCurrent
1180283
CY2023Q4 ptpi Prepaid Purchase Commitment Asset Current
PrepaidPurchaseCommitmentAssetCurrent
704729
CY2024Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
187263
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
234459
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
86547
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
111476
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1894963
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2033980
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
12244484
CY2023 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3272747
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
8971737
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1430566
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
7541171
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
509133
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.75
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y5M15D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
66000
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
1370058
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1754329
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1442186
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1212871
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
996636
CY2024Q2 ptpi Finite Lived Intangible Assets Amortization Expense After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
765091
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
7541171
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1400000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1600000
CY2024Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
700000
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
800000
CY2024Q2 ptpi Accrued Product Returns
AccruedProductReturns
4944502
CY2023Q4 ptpi Accrued Product Returns
AccruedProductReturns
4178176
CY2024Q2 ptpi Accrued Contract Rebates
AccruedContractRebates
48552
CY2023Q4 ptpi Accrued Contract Rebates
AccruedContractRebates
128562
CY2024Q2 ptpi Due To Third Party Logistic Provider
DueToThirdPartyLogisticProvider
62284
CY2023Q4 ptpi Due To Third Party Logistic Provider
DueToThirdPartyLogisticProvider
75727
CY2024Q2 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
964418
CY2023Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
665184
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
15000
CY2024Q2 ptpi Accrued Research And Development Fee Current
AccruedResearchAndDevelopmentFeeCurrent
601952
CY2023Q4 ptpi Accrued Research And Development Fee Current
AccruedResearchAndDevelopmentFeeCurrent
100668
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
51883
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
509133
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.75
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y2M23D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
454600
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.15
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y10M24D
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
197215
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
173652
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
0
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16834
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
43316
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
8203839
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
14.93
CY2023 ptpi Class Of Warrant Or Right Remaining Contractual Term
ClassOfWarrantOrRightRemainingContractualTerm
P4Y3M18D
ptpi Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
-11768
ptpi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Expired
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired
-261.18
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
8192071
CY2024Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
14.57
ptpi Class Of Warrant Or Right Remaining Contractual Term
ClassOfWarrantOrRightRemainingContractualTerm
P3Y9M18D
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10739395
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1214182
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10739395
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1214182
CY2024Q2 ptpi Percentage Of Project Work Completed Under Research Contract
PercentageOfProjectWorkCompletedUnderResearchContract
0.82
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2810276
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
660939
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4998088
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1924750
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1435677
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
3348000
us-gaap Interest Income Operating
InterestIncomeOperating
271210
ptpi Interest Expense On Promissory Notes
InterestExpenseOnPromissoryNotes
234721
us-gaap Net Income Loss
NetIncomeLoss
-2824689
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4511983
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1064599
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4380231
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1185668
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1653590
us-gaap Interest Income Operating
InterestIncomeOperating
119241
ptpi Interest Expense On Promissory Notes
InterestExpenseOnPromissoryNotes
278966
us-gaap Net Income Loss
NetIncomeLoss
-3931830
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1421471
CY2024Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
329110
CY2024Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2286630
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
368798
CY2024Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
717838
CY2024Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1614000
CY2024Q2 us-gaap Interest Income Operating
InterestIncomeOperating
119391
CY2024Q2 ptpi Interest Expense On Promissory Notes
InterestExpenseOnPromissoryNotes
114512
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-662026
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1994011
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
513857
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2249592
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
866575
CY2023Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
826795
CY2023Q2 us-gaap Interest Income Operating
InterestIncomeOperating
52924
CY2023Q2 ptpi Interest Expense On Promissory Notes
InterestExpenseOnPromissoryNotes
136799
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2546683
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1421471
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1994011
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2810276
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4511983
CY2024Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
7541171
CY2024Q2 us-gaap Assets
Assets
25169274
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
8971737
CY2023Q4 us-gaap Assets
Assets
33795795
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.25
CY2023Q4 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
348711
CY2023Q4 ptpi Issuance Exceeded Percentage Limit On Common Stock Issued And Outstanding
IssuanceExceededPercentageLimitOnCommonStockIssuedAndOutstanding
0.05
CY2024Q2 us-gaap Embedded Derivative Liability Measurement Input
EmbeddedDerivativeLiabilityMeasurementInput
0.205
CY2024Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
216798
CY2024Q2 ptpi Temporary Equity Dividends At Stated Rate
TemporaryEquityDividendsAtStatedRate
153842
us-gaap Dividends Preferred Stock
DividendsPreferredStock
812303
ptpi Temporary Equity Dividends At Stated Rate
TemporaryEquityDividendsAtStatedRate
754962
ptpi Reversal Of Temporary Equity Dividends At Stated Value
ReversalOfTemporaryEquityDividendsAtStatedValue
57341
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001410578-24-001437-index-headers.html Edgar Link pending
0001410578-24-001437-index.html Edgar Link pending
0001410578-24-001437.txt Edgar Link pending
0001410578-24-001437-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20240630.xsd Edgar Link pending
tmb-20240630x10q.htm Edgar Link pending
tmb-20240630xex31d1.htm Edgar Link pending
tmb-20240630xex31d2.htm Edgar Link pending
tmb-20240630xex32.htm Edgar Link pending
tmb-20240630_def.xml Edgar Link unprocessable
tmb-20240630_lab.xml Edgar Link unprocessable
tmb-20240630_pre.xml Edgar Link unprocessable
tmb-20240630x10q_htm.xml Edgar Link completed
tmb-20240630_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable